10-K: GlucoTrack, Inc. 2023 Annual Report: Focus Shifts to Implantable CGM Amidst Financial Challenges

GlucoTrack, Inc.'s 2023 annual report highlights a strategic shift towards implantable continuous glucose monitoring (CGM) technology, alongside ongoing financial losses and concerns about the company's ability to continue as a going concern.

Summary

• GlucoTrack, Inc. is a medical device company transitioning its focus to developing an implantable continuous glucose monitor (CGM).
• The company has abandoned its previous non-invasive glucose monitoring device, GlucoTrack 2.0, due to market trends favoring CGM technology.
• A feasibility study demonstrated the potential for a two-year implant life for their new CGM sensor.
• The company completed an initial animal study with positive results, showing good functionality and safety.
• GlucoTrack plans to initiate a long-term animal trial and begin development of a commercial device in late 2024.
• The company anticipates a regulatory submission in late 2024 for a first-in-human study.
• GlucoTrack is also developing a mobile app and cloud platform to manage diabetes data.
• The company reported a net loss of approximately $7.1 million for 2023, compared to $4.4 million in 2022.
• As of December 31, 2023, the company had an accumulated deficit of approximately $109.8 million.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash on hand.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the technology and product development, the financial situation and going concern issues are significant concerns. The shift in strategy is positive, but the company faces substantial risks and challenges.

Positives

• The company has successfully completed a feasibility study demonstrating a minimum two-year implant life for its CGM sensor.
• Initial animal studies have shown good functionality and safety of the implantable CGM.
• The company is developing a mobile app and cloud platform to enhance the user experience and potentially generate additional revenue.
• GlucoTrack has a strong management team with experience in medical device development and commercialization.
• The company has secured a development and manufacturing agreement with Cirtec Medical, a leading medical device solutions provider.

Negatives

• The company has a history of operating losses and has not generated material revenue from product sales.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's stock may be delisted from Nasdaq if it fails to comply with continued listing standards.
• The company is highly dependent on the success of its implantable CGM product, which is still under development and has not yet received regulatory approval.
• The company faces intense competition from established medical device companies.

Risks

• The company may not be able to obtain additional financing on acceptable terms.
• Clinical trials for the implantable CGM may be delayed or unsuccessful.
• The company may not receive regulatory approval for its CGM product.
• The market may not be receptive to the company's CGM product, even if it receives regulatory approval.
• The company may face product liability lawsuits.
• The company relies on third parties for manufacturing and supply of its product.
• The company may be subject to economic, political, regulatory and other risks associated with international operations.
• The company may not be able to enforce covenants not-to-compete under current Israeli law.
• The company's intellectual property may not be adequately protected.
• The company may be subject to claims that its employees or consultants have wrongfully used or disclosed alleged trade secrets.
• Security threats to the company's information technology infrastructure could expose it to liability and damage its reputation and business.

Future Outlook

The company plans to initiate a long-term animal trial and begin development of a commercial device in late 2024, with a regulatory submission anticipated in late 2024 for a first-in-human study in Q1 2025. They also plan to develop a mobile app and cloud platform for data management and potential monetization.

Management Comments

• The company is focused on developing an implantable CGM for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients.
• The company believes its technology has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors.
• The company intends to continue to invest in its talent and to expand and strengthen all areas within the Company.

Industry Context

The shift to CGM technology reflects a broader trend in the diabetes management market, with clinical guidelines increasingly recommending CGM over point-in-time monitoring. The company's focus on an implantable CGM addresses some of the barriers to adoption of current CGM systems, such as the hassle of wearing devices and discomfort.

Comparison to Industry Standards

• The company's implantable CGM is designed to compete with existing transcutaneous CGM systems from Abbott, DexCom, and Medtronic, which have sensor longevities of 7-15 days and require a wearable component.
• The company's device also competes with Senseonics' implantable CGM, which lasts up to 180 days but requires twice-daily fingerstick calibration.
• GlucoTrack's goal of a two-year implant life without a wearable component is a significant differentiator from current market offerings.
• The company's intravascular approach, with a lead placed directly into a blood vessel, aims to provide more accurate glucose measurements with zero lag time compared to interstitial fluid measurements of other CGM systems.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into an exchange agreement with Andrew Garrett Inc and affiliates, exchanging warrants for shares of common stock.
• The company acquired intellectual property related to a long-term implantable CGM from Paul V. Goode, the Chief Executive Officer.
• Mark Tapsak, an officer, was providing services including the laboratory and consultants via Tapsak Enterprises, LLC to the Company.
• James Cardwell, an officer and CFO, is also the COO of CFO Squad LLC providing financial reporting services to the Company.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's financial challenges.
• Employees may be affected by potential cost-cutting measures or restructuring due to the company's financial situation.
• Customers (potential patients) may benefit from the development of a new and improved CGM technology.
• Suppliers and creditors face the risk of non-payment due to the company's financial instability.

Next Steps

• Initiate a long-term animal trial for the implantable CGM.
• Begin development of a commercial device in late 2024.
• Submit a regulatory application in late 2024 for a first-in-human study.
• Continue development of the mobile app and cloud platform.
• Identify potential clinical sites and obtain regulatory approval for the first-in-human trial.
• Refine implant, explant, and replacement procedures and associated tool set.
• Continue to research materials and techniques to reduce overall system cost.

Key Dates

Keywords

implantable CGM, continuous glucose monitor, diabetes management, medical device, regulatory approval, clinical trials, financial loss, going concern, intellectual property, stock delisting